Loss of Two-Pore Channel 2 (TPC2) Expression Increases the Metastatic Traits of Melanoma Cells by a Mechanism Involving the Hippo Signalling Pathway and Store-Operated Calcium Entry

• Published in: Cancers Vol. 12; no. 9; p. 2391
• Main Authors: D’Amore, Antonella, Hanbashi, Ali Ahmed, Di Agostino, Silvia, Palombi, Fioretta, Sacconi, Andrea, Voruganti, Aniruddha, Taggi, Marilena, Canipari, Rita, Blandino, Giovanni, Parrington, John, Filippini, Antonio
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.09.2020; MDPI
• Subjects: Angiogenesis; Cadherins; Calcium channels; Calcium influx; Cancer metastasis; Cell adhesion & migration; Cell cycle; Cell growth; CRISPR; Cyclin-dependent kinases; Endosomes; Gelatinase B; Gene expression; Genes; Genetic aspects; Genomes; Health aspects; Ion channels; Kinases; Lysosomes; Medical prognosis; Melanoma; Melanosomes; Mesenchyme; Metastases; Metastasis; N-Cadherin; Orai1 protein; Plasma; Protein kinase C; Proteins; RNA-mediated interference; Signal transduction; Skin cancer; Transcription factors; Tumorigenesis; Vimentin; Yes-associated protein; United Kingdom
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12092391

Melanoma is one of the most aggressive and treatment-resistant human cancers. The two-pore channel 2 (TPC2) is located on late endosomes, lysosomes and melanosomes. Here, we characterized how TPC2 knockout (KO) affected human melanoma cells derived from a metastatic site. TPC2 KO increased these cells’ ability to invade the extracelullar matrix and was associated with the increased expression of mesenchymal markers ZEB-1, Vimentin and N-Cadherin, and the enhanced secretion of MMP9. TPC2 KO also activated genes regulated by YAP/TAZ, which are key regulators of tumourigenesis and metastasis. Expression levels of ORAI1, a component of store-operated Ca2+ entry (SOCE), and PKC-βII, part of the HIPPO pathway that negatively regulates YAP/TAZ activity, were reduced by TPC2 KO and RNA interference knockdown. We propose a cellular mechanism mediated by ORAI1/Ca2+/PKC-βII to explain these findings. Highlighting their potential clinical significance, patients with metastatic tumours showed a reduction in TPC2 expression. Our research indicates a novel role of TPC2 in melanoma. While TPC2 loss may not activate YAP/TAZ target genes in primary melanoma, in metastatic melanoma it could activate such genes and increase cancer aggressiveness. These findings aid the understanding of tumourigenesis mechanisms and could provide new diagnostic and treatment strategies for skin cancer and other metastatic cancers.